Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production

Histopathology. 2011 Sep;59(3):562-4. doi: 10.1111/j.1365-2559.2011.03923.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Arthritis, Rheumatoid / complications
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / metabolism
  • Carcinoma, Renal Cell / pathology
  • Clinical Trials as Topic
  • Depression / complications
  • Female
  • Humans
  • Hypertension / complications
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / metabolism
  • Kidney Neoplasms / pathology
  • Middle Aged
  • Neoadjuvant Therapy / methods
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use*
  • Sorafenib
  • Vascular Endothelial Growth Factor A / biosynthesis*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Sorafenib